Colistin sulfate CAS NO.1264-72-8

Product description

Function

1. Oral formulations is suitable for treating respiratory infections, abdominal infection, female reproductive tract infections, pelvic infections,
skin and soft tissue infections caused by sensitive Staphylococcus aureus and Streptococcus pneumoniae. 

2. In addition to the treatment of the above infections, injected formulations are suitable for treatment of severe infections caused by
streptococcus, pneumococcus and staphylococcus such as the surgical adjuvant therapy of septicemia, bone and joint infections, chronic bone
and joint infections and Staphylococcus-induced acute hematogenous osteomyelitis. 

3. Lincomycin hydrochloride may also be used for the treatment of infectious diseases in patients allergic to penicillin or not suitable for
administration of penicillin-type drugs.

Wuhan BJM Pharm Inc. was found in 2013, located in Hubei Province, where has long history, rich culture, convenient traffic, beautiful environment and preferential policy.

We have two factories in Dezhou , Shandong and Xianning, Hubei. The factory covers an area of 48,000 square meters with the building area of 26,000 square meters. We are specialized in the manufacture of pharmaceutical intermediates and cosmetic additives with good inspection equipments and innovative R & D capability.

In 2006, We established Lingxian Microworld Chemical New Material Co,.Ltd.

In 2008, We passed ISO quality system certificate

In 2013, We established Wuhan Benjamin Pharmaceutical Chemical Co.,Ltd , and obtain self-operation Import & Export right, mainly responsible for domestic and foreign business. At the same time, we set up R&D lab in Wuhan,Hubei province, can undertake various custom synthesis of intermediates and APIs.

In 2016,  obtain a registered trademark “ BJM ”.

In 2017, we applied for the invention patent of TRIS, and in 2018, we applied for the invention patent of ERDOSTAN intermediate（DL-HOMO）. At present, we have6 patents passed the preliminary examination, and 4 patents are under examination and approval.

In 2019, we purchased a R&D and office building with a total area of 2500 square meters, as our headquarters in Wuhan.

In 2020, we registered BJM Pharm Yunmeng Co., Ltd,  and the new production base settled in Geputan chemical park with  a total area of 50000 square meters.

We are specialized in the R&D ,production and sales of Erdosteine ,Pirfenidone, Telmisartan, Letrozole , Sitagliptin phosphate, Dapagliflozin , Tris , IPTG and related intermediates.

We stick to the principle as: people-oriented, customer first, Hope to establish a win-win business relationship with all friends.